BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35947641)

  • 1. Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function.
    Macha SJ; Koneru B; Burrow TA; Zhu C; Savitski D; Rahman RL; Ronaghan CA; Nance J; McCoy K; Eslinger C; Reynolds CP
    Cancer Res; 2022 Sep; 82(18):3345-3358. PubMed ID: 35947641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.
    Koneru B; Farooqi A; Nguyen TH; Chen WH; Hindle A; Eslinger C; Makena MR; Burrow TA; Wilson J; Smith A; Pilla Reddy V; Cadogan E; Durant ST; Reynolds CP
    Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34408079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative lengthening of telomeres does exist in various canine sarcomas.
    Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M
    Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
    Farooqi AS; Dagg RA; Choi LM; Shay JW; Reynolds CP; Lau LM
    J Neurooncol; 2014 Aug; 119(1):17-26. PubMed ID: 24792489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma.
    George SL; Parmar V; Lorenzi F; Marshall LV; Jamin Y; Poon E; Angelini P; Chesler L
    J Exp Clin Cancer Res; 2020 May; 39(1):78. PubMed ID: 32375866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of p53 and/or AKT as a new therapeutic approach specifically targeting ALT cancers.
    Ge Y; Wu S; Zhang Z; Li X; Li F; Yan S; Liu H; Huang J; Zhao Y
    Protein Cell; 2019 Nov; 10(11):808-824. PubMed ID: 31115790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative lengthening of telomeres in cancer stem cells in vivo.
    Bojovic B; Booth RE; Jin Y; Zhou X; Crowe DL
    Oncogene; 2015 Jan; 34(5):611-20. PubMed ID: 24531712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
    Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
    Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta.
    Novakovic B; Napier CE; Vryer R; Dimitriadis E; Manuelpillai U; Sharkey A; Craig JM; Reddel RR; Saffery R
    Mol Hum Reprod; 2016 Nov; 22(11):791-799. PubMed ID: 27604461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Loss of
    Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
    Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas.
    Ulaner GA; Hoffman AR; Otero J; Huang HY; Zhao Z; Mazumdar M; Gorlick R; Meyers P; Healey JH; Ladanyi M
    Genes Chromosomes Cancer; 2004 Oct; 41(2):155-62. PubMed ID: 15287028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomeres and telomerase in sarcomas.
    Matsuo T; Shimose S; Kubo T; Fujimori J; Yasunaga Y; Ochi M
    Anticancer Res; 2009 Oct; 29(10):3833-6. PubMed ID: 19846916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
    Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
    J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: implications for telomere-based therapies.
    Gocha AR; Nuovo G; Iwenofu OH; Groden J
    Am J Pathol; 2013 Jan; 182(1):41-8. PubMed ID: 23260199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers.
    Henson JD; Reddel RR
    FEBS Lett; 2010 Sep; 584(17):3800-11. PubMed ID: 20542034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT-associated PML bodies.
    Jeyapalan JN; Mendez-Bermudez A; Zaffaroni N; Dubrova YE; Royle NJ
    Int J Cancer; 2008 Jun; 122(11):2414-21. PubMed ID: 18311780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.
    Flynn RL; Cox KE; Jeitany M; Wakimoto H; Bryll AR; Ganem NJ; Bersani F; Pineda JR; SuvĂ  ML; Benes CH; Haber DA; Boussin FD; Zou L
    Science; 2015 Jan; 347(6219):273-7. PubMed ID: 25593184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.
    Heaphy CM; Subhawong AP; Hong SM; Goggins MG; Montgomery EA; Gabrielson E; Netto GJ; Epstein JI; Lotan TL; Westra WH; Shih IeM; Iacobuzio-Donahue CA; Maitra A; Li QK; Eberhart CG; Taube JM; Rakheja D; Kurman RJ; Wu TC; Roden RB; Argani P; De Marzo AM; Terracciano L; Torbenson M; Meeker AK
    Am J Pathol; 2011 Oct; 179(4):1608-15. PubMed ID: 21888887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells.
    Zhao S; Wang F; Liu L
    Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres.
    Onitake Y; Hiyama E; Kamei N; Yamaoka H; Sueda T; Hiyama K
    J Pediatr Surg; 2009 Dec; 44(12):2258-66. PubMed ID: 20006006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.